Taiwan · Delayed Price · Currency is TWD Sinew Pharma Company Description
Sinew Pharma Inc., a biopharmaceutical company, focuses on the research, development, and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases.
The company’s products include SNP-610 drug, which is in Phase IIa clinical trial and SNP-630 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan.
It is also developing SNP-810 is in phase II clinical trial for use in pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetaminophen poisoning, and SNP-830 and SNP-840, which in pre-clinical trial are used as hepatotoxicity-free analgesic medicines in the United States.
Sinew Pharma Inc. was founded in 2014 and is based in Taipei City, Taiwan.
| Country | Taiwan |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 52 |
| CEO | Kai-Min Chu |
Contact Details
Address: C516, Building C Taipei, 11571 Taiwan | |
| Phone | 886 2 2788 5365 |
| Website | sinewpharma.com |
Stock Details
| Ticker Symbol | 6634 |
| Exchange | Taipei Exchange |
| Fiscal Year | January - December |
| Reporting Currency | TWD |
| ISIN Number | TW0006634009 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Kai-Min Chu M.D., Ph.D. | Chairman and Chief Executive Officer |
| Cheng-Hui Hsiung Ph.D. | Chief Operating Officer |
| Tzu-Wen Chen | Chief Financial Officer and Accounting Supervisor |
| Hsin-Tien Ho | Chief Technology Officer |